Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06935994
PHASE2

Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

Sponsor: Taichung Veterans General Hospital

View on ClinicalTrials.gov

Summary

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease worldwide and a significant public health issue. MASLD may progress to liver cirrhosis and/or hepatocellular carcinoma. Although previous evidence suggests that aspirin has antisteatotic and antifibrotic effects on the liver, a randomized controlled trial assessing long-term efficacy and safety of aspirin in MASLD patients has yet to be conducted. This study aims to conduct a randomized controlled trial to evaluate the efficacy of aspirin in treating MASLD.

Official title: Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2025-05-05

Completion Date

2032-12-31

Last Updated

2025-05-11

Healthy Volunteers

No

Interventions

DRUG

Aspirin 81 mg Enteric Coated Tab - 1 tablet

Participants will be randomly assigned in a 1:1 ratio to receive daily low-dose (81mg) aspirin or a placebo

DRUG

Placebo

Participants will be randomly assigned in a 1:1 ratio to receive daily low-dose (81mg) aspirin or a placebo

Locations (1)

Taichung Veterans General Hospital

Taichung, Taiwan, Taiwan